A 600 mg daily dose of the menin inhibitor #ziftomenib, combined with venetoclax and azacitidine, demonstrated robust clinical activity in patients with newly diagnosed, NPM1-mutated #AcuteMyeloidLeukemia #AML at an 84% CRc and an MRD-negative rate of 54%: https://ow.ly/E5Nb50XMwL0
#HemeSky #OncSky

Hematology Weekly News – April 14th 2025 🩸 Hematology Headlines You Shouldn’t Miss This Week Welcome to this week’s Hematology Research Update! This episode dives deep into […] The post Hematology Weekly News – April 14th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Hematology Weekly News – April 14th 2025 #News #hematology #CART #AML #Ziftomenib Comment below!

Hematology Weekly News – April 14th 2025 🩸 Hematology Headlines You Shouldn’t Miss This Week Welcome to this week’s Hematology Research Update! This episode dives deep into […] The post Hematology Weekly News – April 14th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Hematology Weekly News – April 14th 2025 #News #hematology #CART #AML #Ziftomenib Comment below!

Hematology Weekly News – April 14th 2025 🩸 Hematology Headlines You Shouldn’t Miss This Week Welcome to this week’s Hematology Research Update! This episode dives deep into […] The post Hematology Weekly News – April 14th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Hematology Weekly News – April 14th 2025 #News #hematology #CART #AML #Ziftomenib Comment below!